Search
Healthy Clinical Trials in Nashville, TN
A listing of 2 Healthy clinical trials in Nashville, TN actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 2 of 2
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Healthy
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Nashville, Tennessee, currently has 2 active clinical trials seeking participants for Healthy research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
NAD+ Aging Study
Recruiting
The HEALING Lab at the University of Rhode Island is seeking volunteers between the age of 40-80 for a NAD+ aging study. Participants will receive $300 for completing a 5-week study, which involves taking an oral supplement (either a sugar pill or NAD+ supplement) for 4 weeks between two in-person sessions. To participate in this study, you cannot be taking hormones, pregnant, or breastfeeding.
Conditions:
Healthy
Healthy Volunteers
Featured Trial
Respiratory Syncytial Virus (RSV) Treatment Study
Recruiting
We’re seeking volunteers to participate in a RSV treatment study.
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Conditions:
RSV
Respiratory Syncytial Virus (RSV)
Healthy
Healthy Volunteers
Healthy Subjects
Featured Trial
Respiratory Syncytial Virus (RSV) Treatment Study
Recruiting
We’re seeking volunteers to participate in a RSV treatment study.
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Conditions:
RSV
Respiratory Syncytial Virus (RSV)
Healthy
Healthy Volunteers
Healthy Subjects
Featured Trial
Evaluating an Investigational Treatment for Hidradenitis Suppurativa
Recruiting
The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.
Conditions:
All Conditions
Hidradenitis suppurativa (Skin disorder)
Dermatology
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Recruiting
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify... Read More
Gender:
ALL
Ages:
Between 15 years and 80 years
Trial Updated:
02/14/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers
Recruiting
This is a Phase 1, single-center, open-label, single-arm, dose-escalation positron emission tomography study to assess the safety and tolerability, immunogenicity, Pharmacokinetics, dosimetry, and biodistribution after GEH200521 (18F) Injection is co-administered with GEH200520 Injection in healthy volunteers.
The estimated study duration for each subject is approximately 28 days.
The primary study objective is to evaluate the safety and tolerability of the IMPs, the selected mass doses of GEH... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Healthy Volunteers
1 - 2 of 2